MedPage Today December 31, 2025
Program will cover the drugs for weight management
The Trump administration announced a new demonstration program aimed at easing access to GLP-1 receptor agonists for enrollees in Medicare Part D and Medicaid plans, but experts say it’s unclear how popular or effective it will be.
The program, known as Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE), is designed to increase access to GLP-1 drugs for purposes of “weight management and metabolic health improvement” for Medicare Part D and Medicaid enrollees. BALANCE “builds upon our historic Most Favored Nations drug pricing deals’ goal of democratizing access to weight-loss medication, which has been out of reach for so many in need,” Mehmet Oz, MD, MBA, administrator of CMS, said...
Today's Sponsors
Today's Sponsor